Bacteriophages to the Rescue

Phage therapy is but one example of using biological entities to reduce our reliance on antibiotics and other failing chemical solutions.

Written byEmily Monosson
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ISLAND PRESS, JUNE 2017This year I gave a presentation to public-health students at a university about options for controlling pests and pathogens that didn’t depend on industrial-age chemicals such as antibiotics and pesticides. When I asked if they’d ever heard of phage therapy—the use of bacteria-attacking viruses to fight infection—I was met with blank stares. When I finished sharing stories of desperate patients miraculously cured of antibiotic-resistant infections within days, I sensed a bit of skepticism, as if the crowd’s politeness was keeping them from asking: “If it’s so effective, how come we’ve never heard of this?” In this age of alternate truths and quack cures, it’s an appropriate question.

But phage therapy is nothing new, nor is it some fringe remedy. It was first used to cure Shigella infections early in the 20th century, to miraculous effect (although at the time, scientists were unaware of the nature of viruses). Once treated with phages isolated from fecal samples of spontaneously recovering dysentery sufferers, patients’ Shigella-induced fevers and bloody stools subsided within 24 hours. (See “Viral Soldiers,” The Scientist, January 2016.) Within a decade, pharmaceutical companies on both sides of the Atlantic began developing various phage therapies. But then came antibiotics. And poor production practices by some pharmaceutical companies (some commercial products in the U.S. were found to be lacking in potency, for example) led to a couple of damning reviews of phage therapy in the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

July/August 2017

DNA Erector Sets

New blueprints for the double helix

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies